Skip to main content

Advertisement

SpringerLink
Log in

Metabolic syndrome associated with HIV and highly active antiretroviral therapy

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

The introduction of highly active antiretroviral therapy (HAART) has significantly improved the clinical outcome of HIV disease with increased survival rates. However, some HAART regimens, especially those including protease inhibitors, have been shown to cause in a high proportion of HIV-infected patients metabolic (dyslipidemia, insulin resistance) and somatic (lipodystrophy/lipoatrophy) changes that are associated with an increased risk of cardiovascular disease (coronary artery disease and stroke). The pathogenesis of HAART-associated metabolic syndrome and of its atherogenic profile is complex, and several factors are involved, including direct effects of HAART on lipid metabolism, endothelial and adipocyte cell function, activation of proinflammatory cytokines, and mitochondrial dysfunction. A better understanding of the molecular mechanisms responsible for this syndrome will lead to the discovery of new drugs that will reduce the incidence of lipodystrophy and related metabolic complications in HIV-infected patients facing long-term HAART.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51–F58.

    Article  PubMed  CAS  Google Scholar 

  2. Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48–62.

    Article  PubMed  CAS  Google Scholar 

  3. Samaras K, Wand H, Law M, et al.: Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using international Diabetes Foundation and Adult Treatment Panel III criteria: association with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein and hypoadiponectinemia. Diabetes Care 2007, 30:113–119.

    Article  PubMed  CAS  Google Scholar 

  4. Wand H, Calmy A, Carey DL, et al.: Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007, 21:2445–2453.

    Article  PubMed  CAS  Google Scholar 

  5. Gougeon ML, Penicaud L, Fromenty B, et al.: Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 2004, 9:161–177.

    PubMed  CAS  Google Scholar 

  6. Carr A, Samaras K, Chisholm DJ, Cooper DA: Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351:1881–1883.

    Article  PubMed  CAS  Google Scholar 

  7. Fauvel J, Bonnet E, Ruidavets JB, et al.: An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001, 15:2397–2406.

    Article  PubMed  CAS  Google Scholar 

  8. Bonnet E, Ruidavets JB, Tuech J, et al.: Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab 2001, 86:296–302.

    Article  PubMed  CAS  Google Scholar 

  9. Caron M, Auclair M, Sterlingot H, et al.: Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003, 17:2437–2444.

    Article  PubMed  CAS  Google Scholar 

  10. Jones SP, Janneh O, Back DJ, Pirmohammed M: Altered adipocytokines gene expression in murine 3T3-F442A adipocyte treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 2003, 8:L11.

    Google Scholar 

  11. Myarcik DC, McNurlan MA, Steigbigel RT, et al.: Association of severe insulin resistance with body loss and limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J AIDS 2000, 25:312–321.

    Google Scholar 

  12. Rietschel P, Hadigan C, Corcoran C, et al.: Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. Clin Endocrinol Metab 2001, 86:504–510.

    Article  CAS  Google Scholar 

  13. Lo JC, Mulligan K, Noor MA, et al.: The effect of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001, 86:3480–3487.

    Article  PubMed  CAS  Google Scholar 

  14. Caron M, Auclair M, Lagathu C, et al.: The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte function in vitro. AIDS 2004, 18:2127–2136.

    Article  PubMed  CAS  Google Scholar 

  15. Villarroya F, Domingo P, Giralt M: Lipodystrophy associated with highly active antiretroviral therapy for HIV infection: the adipocyte as target of antiretroviral-induced mitochondrial toxicity. Trends Pharmacol Sci 2005, 26:88–93.

    Article  PubMed  CAS  Google Scholar 

  16. Lewis W, Kohler J, Hosseini S, et al.: Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol-gamma hypothesis. AIDS 2006, 20:675–684.

    Article  PubMed  CAS  Google Scholar 

  17. Seminari E, Tinelli C, Minoli L, et al.: Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients. Antivir Ther 2002, 7:175–180.

    PubMed  Google Scholar 

  18. McComsey GA, Paulsen D, Lonergan JT, et al.: Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005, 19:15–23.

    Article  PubMed  CAS  Google Scholar 

  19. Vigouroux C, Maachi M, Nguyen TH, et al.: Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003, 17:1503–1511.

    Article  PubMed  CAS  Google Scholar 

  20. Haque WA, Shimomura I, Matsuzawa Y, Garg A: Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002, 87:2395–2398.

    Article  PubMed  CAS  Google Scholar 

  21. Addy CL, Gavrila A, Tsiodras S, et al.: Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003, 88:627–636.

    Article  PubMed  CAS  Google Scholar 

  22. Hadigan C, Meigs JB, Rabe J, et al.: Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001, 86:939–943.

    Article  PubMed  CAS  Google Scholar 

  23. Witz M, Lehmann J, Korzets Z: Acute brachial artery thrombosis as the initial manifestations of human immunodeficiency virus infection. Am J Hematol 2000, 64:137–139.

    PubMed  CAS  Google Scholar 

  24. Sullivan PS, Dworkin MS, Jones JL, Hooper WC: Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000, 14:321–324.

    Article  PubMed  CAS  Google Scholar 

  25. Fiala M, Murphy T, MacDougall J, et al.: HAART drugs induces mitochondrial damage and intercellular gaps ans gp120 causes apoptosis. Cardiovasc Toxicol 2005, 4:327–337.

    Article  Google Scholar 

  26. Stein JH, Klein MA, Bellehumeur JL, et al.: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001, 104:257–262.

    PubMed  CAS  Google Scholar 

  27. Zhong DS, Lu XH, Conklin BS, et al.: HIV protease ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 2002, 22:1560–1566.

    Article  PubMed  CAS  Google Scholar 

  28. Roling J, Schmid H, Fischereder M, et al.: HIV-associated renal diseases and highly active antiretriviral therapyinduced nephropathy. Clin Infect Dis 2006, 42:1488–1495.

    Article  PubMed  CAS  Google Scholar 

  29. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143–3421.

    Google Scholar 

  30. Gazzaruso C, Bruno R, Garzaniti A, et al.: Hypertension among HIV patients: prevalence and relationship to insulin resistance and metabolic syndrome. J Hypertens 2003, 21:1377–1382.

    Article  PubMed  CAS  Google Scholar 

  31. Sattler FR, Qian D, Louie S, et al.: Elevated blood pressure in subjects with lipodystrophy. AIDS 2001, 15:2001–2010.

    Article  PubMed  CAS  Google Scholar 

  32. Maggi P, Serio G, Epifani G, et al.: Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000, 14:F123–F128.

    Article  PubMed  CAS  Google Scholar 

  33. Depairon M, Chessex S, Sudre P, et al.: Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 2001, 15:329–334.

    Article  PubMed  CAS  Google Scholar 

  34. Hsue PY, Lo JC, Franklin A, et al.: Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004, 109:1603–1608.

    Article  PubMed  Google Scholar 

  35. Currier JS, Kendall MA, Zackin R, et al.: Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005, 19:927–933.

    Article  PubMed  CAS  Google Scholar 

  36. Jerico C, Knobel H, Calvo N, et al.: Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy. Stroke 2006, 37:812–817.

    Article  PubMed  Google Scholar 

  37. Holmberg SD, Moorman AC, Williamson JM, et al.: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002, 360:1747–1748.

    Article  PubMed  CAS  Google Scholar 

  38. Bozzette SA, Ake CF, Tam HK, et al.: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702–710.

    Article  PubMed  CAS  Google Scholar 

  39. Mary-Krause M, Cotte L, Simon A, et al.: Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003, 17:2479–2486.

    Article  PubMed  Google Scholar 

  40. Barbaro G, Di Lorenzo G, Cirelli A, et al.: An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV receiving highly active antiretroviral therapy. Clin Ther 2003, 25:2405–2418.

    Article  PubMed  CAS  Google Scholar 

  41. The DAD Study Group, Friis-Møller N, Reiss P, et al.: Class of antiretriviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723–1735.

    Article  PubMed  Google Scholar 

  42. Dubé MP, Stein JH, Aberg JA, et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trial Groups. Clin Infect Dis 2004, 37:613–627.

    Article  Google Scholar 

  43. Volberding P, Murphy R, Barbaro G, et al.: The pavia consensus statement. AIDS 2003, 17(Suppl 1):S170–S179.

    PubMed  Google Scholar 

  44. Iacobellis G, Sharma AM, Pellicelli AM, et al.: Epicardial adipose tissue is related to carotid intima-media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome. Curr HIV Res 2007, 5:275–279.

    Article  PubMed  CAS  Google Scholar 

  45. Iacobellis G, Pellicelli AM, Sharma AM, et al.: Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. Am J Cardiol 2007, 99:1470–1472.

    Article  PubMed  Google Scholar 

  46. van Wijk JP, de Koning EJ, Cabezas MC, et al.: Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005, 143:337–346.

    Article  PubMed  Google Scholar 

  47. Carr A, Workman C, Carey D, et al.: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomized, double-blind, placebo-controlled trial. Lancet 2004, 363:429–438.

    Article  PubMed  CAS  Google Scholar 

  48. Hadigan C, Yawetz S, Thomas A, et al.: Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized controlled trial. Ann Intern Med 2004, 140:786–794.

    PubMed  CAS  Google Scholar 

  49. Cavalcanti RB, Raboud J, Shen S, et al.: A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis 2007, 195:1754–1761.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Unit, Department of Medical Pathophysiology, University La Sapienza, Viale Anicio Gallo 63, 00174, Rome, Italy

    Giuseppe Barbaro

Authors
  1. Giuseppe Barbaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gialuca Iacobellis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Barbaro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barbaro, G., Iacobellis, G. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 9, 37–42 (2009). https://doi.org/10.1007/s11892-009-0008-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-009-0008-7

Keywords

Search

Navigation